Relief of symptoms in patients with atrial fibrillation (AF) is challenging. 1 In certain patients, a rhythm control strategy has been shown to improve quality of life 2, 3 and increase exercise capacity. 4 Randomized clinical trials have, to date, failed to identify a survival advantage with a rhythm control strategy 5, 6 ; therefore, rhythm control is typically reserved for patients with symptomatic AF despite rate control. Cardioversion has a class I recommendation for patients in AF pursuing a rhythm control strategy. 1 Cardioversion use is also driven by a widely held clinical adage that the first episode of sustained AF should be cardioverted. This is often expressed more colloquially as "everyone deserves at least one attempt at cardioversion and sinus rhythm."
It is generally assumed that with appropriate electrode placement, direct current cardioversion (DCCV) has greater than 95% success with restoration of sinus rhythm. 7 However, without the addition of rhythm control therapies such as antiarrhythmics or ablation, AF recurs in a high percentage of patients within 1 year of cardioversion. [8] [9] [10] Despite the widespread use of cardioversion and its class I guideline indication, there have been few reports of outcomes after cadioversion in contemporary clinical practice. The objective of this analysis is to describe the use of pharmacologic cardioversion and DCCV, in US clinical practice. Moreover, this analysis will describe outcomes after cardioversion, including AF progression, cardiovascular hospitalization, and quality of life.
Methods

Study population
The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) is a national prospective registry of AF in the United States. 11 Enrollment was captured across a variety of practice settings, including primary care, cardiology, and cardiac electrophysiology clinics. Eligible patients were 18 years or older with electrocardiographically confirmed AF. Patients were excluded if they had an acute reversible cause of AF (eg, postoperative AF), had a life expectancy of less than 6 months, or were not capable of at least 2 years of follow-up.
Sites entered data from the medical record into a Web-based case report form at baseline and every 6 months over longitudinal follow-up (minimum of 24 months). Patient demographics, medical history, AF history, AF symptoms, AF treatment strategy, vital signs, laboratory data, imaging data, incident procedures, and adverse events were collected. The Duke Clinical Research Institute was responsible for study design and data management.
There were 10,132 consecutive patients from 176 clinic sites enrolled in ORBIT-AF from June 2010 through August 2011. Patients were excluded from this analysis if they did not have any follow-up data (n = 490), leaving 9,642 patients to be included in this analysis.
Outcomes
Because follow-up visits were not scheduled based on the cardioversion dates, the first follow-up after cardioversion was between 0 and 6 months after cardioversion, whereas the second follow-up after cardioversion was between 6 and 12 months after cardioversion. Hospitalization and mortality at 1 year were the primary efficacy outcomes in this study. Secondary outcomes included AF progression and quality of life. A patient was determined to have AF progression if their classification changed between precardioversion and follow-up from paroxysmal AF (AF terminating spontaneously in b7 days) to persistent (AF lasting N7 days), paroxysmal AF to permanent AF (AF in which the decision has made to abandon rhythm control and pursue rate control), or persistent AF to permanent AF. Patients in the matched, noncardioversion cohort were similarly defined as having AF progression if their AF classification changed between the visit immediately before the matched visit and subsequent follow-up visits (eg, paroxysmal to persistent or persistent to permanent). Symptoms were described using an AF symptom inventory and the European Heart Rhythm Association (EHRA) score 12 in all patients. Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) 13 was captured in a subset of patients (n = 1925 in the overall population and n = 170 cardioversion patients). The precardioversion symptom scores were the scores at the visit immediately preceding cardioversion in the cardioversion cohort and the visit immediately preceding the matched visit in the noncardioverted patients.
Statistical methods
Categorical variables were defined as frequencies and percentages, and differences between the groups were assessed by the χ 2 test. Continuous variables were characterized by median (Q1-Q3), and differences between the groups were determined by the Wilcoxon rank sum test.
A matched cohort was constructed between cardioverted patients and noncardioverted patients. This cohort was used for the evaluation of AF progression, first-time cardioversion, rhythm control therapies in follow-up, symptoms and quality of life after cardioversion, and cardiovascular outcomes after cardioversion. Each case of cardioversion was matched to 3 control (noncardioverted) patients. We implemented sequential stratification matching, identifying matches from the same point in follow-up (visit) at which cardioversion was recorded. Patients had to have an exact match on duration of AF, classification of AF type, and any history of rhythm control based on prior AF ablation and prior or current antiarrhythmic use. A single propensity score (ie, propensity to cardiovert) was then obtained from a logistic regression model for cardioversion and included 23 additional covariates (Appendix 1). Matches were selected from among all available noncardioverted patients at a given visit, based on the closest propensity score. The difference in propensities could be no larger than a caliper of 20% of a standard deviation. Occasionally, 3 adequate matches were not found for each cardioverted patient (2%), so the number of controls is not exactly triple the number of cardioversions. The success of matching was evaluated by displaying the distribution of characteristics along with standardized differences of the matched cohort. Cardioverted patients and matched controls had a very similar distribution of covariates (Appendix 2A-B). Missing data in the covariates used for matching were handled by single imputation, and imputed values were obtained by Markov chain Monte Carlo or regression methods. We fit the model using stratified Cox regression, with strata for the matched pairs, and using the first option that reduced bias in the parameter estimates. Permanent AF patients were excluded when matching, because those patients are not eligible for cardioversion. When matching for cardioverted patients at and after 12 months of follow-up, we excluded new-onset AF patients. A sensitivity analysis was performed among patients who underwent their first cardioversion. For this sensitivity analysis, patients within the matched cohort with prior cardioversion were excluded.
The matched cohorts were used to assess patient symptom scores before and after cardioversion. Patients who had no symptoms by EHRA score at the visit before cardioversion or matching were excluded from this analysis.
All analyses were performed using SAS software (version 9.3; SAS Institute, Cary, NC). The study was approved by the Duke University Institutional Review Board. Janssen Scientific Affairs, LLC (Raritan, NJ) provided financial support for the development of the registry and the funding of this analysis. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
Results
Baseline characteristics
Among 9,642 patients with a median follow-up of 12 (6, 18 [25th, 75th] ) months, 817 (8%) patients underwent 906 cardioversion procedures. Most of the 906 cardioversions (84%) were DCCV, although 53% (429) of the 817 cardioverted patients were on antiarrhythmic medications at the time of cardioversion. There were 112 (12%) cardioversions that were guided by transesophageal echocardiography (TEE), and nearly all of these cardioversions were DCCV (96%). Unmatched patients in the overall cohort undergoing cardioversion were significantly younger (68.6 vs 74.0 years), more likely to have a college education (37.7% vs 30.4%), and more likely to have fatigue as a symptom of AF (37.3% vs 25.3%; all P b .0001) ( Table I) . Unmatched cardioversion patients also had significantly less sinus node dysfunction (11% vs 18.4%), more obstructive sleep apnea (27.2% vs 17.5%), and more severe or disabling EHRA symptoms (25.0% vs 15.5%), and more often received care from an electrophysiologist (28.8% vs 16.1%; all P b .0001). Propensity-matched patients undergoing cardioversion were similar to patients who did not undergo cardioversion with respect to age (69.9 vs 70.2 years, P = .57), baseline symptom burden, and most comorbidities (Table I and Appendix 2).
First-time cardioversions
Within the matched cohort, there were 209 patients who underwent a first-time cardioversion (no history of cardioversion), and there were 604 noncardioverted patients who had never undergone cardioversion. Patients who had a first-time cardioversion had higher rates of 1-year all-cause hospitalization relative to patients who never cardioverted (54% vs 37%, P = .005), as well as higher rates of 1-year cardiovascular hospitalization (41% vs 22%, P b .0001). Among these first-time cardioversion patients, 139 (67%) reported symptoms. At first follow-up, 50% of these patients were in sinus rhythm, compared with 42% (odds ratio [OR] 1.3, P = .24) of noncardioverted patients. At second follow-up, 47% of the cardioverted patients were in sinus rhythm compared with 36% (OR 1.3, P = .21) of noncardioverted patients. Similar to the overall group, AF progression at second follow-up was higher in the cardioverted patients (19%) than in the noncardioverted patients (10%; OR 2.7, P b .001). The baseline EHRA scores of patients undergoing first cardioversion showed that 72% had mild symptoms and 27% had severe or disabling symptoms, which was similar to the matched cohort with 66% having mild symptoms and 32% having severe or disabling symptoms (P = .31). In follow-up of these first-time cardioversion patients, 35% had no symptoms, 41% had mild symptoms, and 24% had severe or disabling symptoms, compared with 33%, 46%, and 15%, respectively, for the matched, noncardioverted patients (P = .21).
Rhythm control therapies in follow-up
There were 152 (35%) matched, cardioverted patients who were not on antiarrhythmics before cardioversion, whereas 612 (52%) noncardioverted patients were not on antiarrhythmics at baseline. Only 28 (18%) patients were subsequently started on an antiarrhythmic after cardioversion. Among the matched cohort, there was a higher portion of cardioverted patients who were on antiarrhythmics (including class I, class III, or ranolazine) at last follow-up (50% vs 40%, P = .001). The cardioversion patients also stopped their antiarrhythmics after cardioversion at nearly twice the rate (22% vs 12%, P b .001). Ablations were uncommon in this patient population, but ablations did occur more frequently in the cardioversion patients (5% vs 2%, P = .006).
Arial fibrillation progression
Among all 817 patients who underwent cardioversion, only 52% of cardioverted patients were in sinus rhythm at first follow-up after cardioversion and only 34% of cardioverted patients were in sinus rhythm at first and second follow-ups after cardioversion. Two-thirds (551 patients) of all cardioverted patients were not treated with an antiarrhythmic medication or ablation in follow-up, and only 151 (31%) of these patients were in sinus rhythm at first and second follow-ups. Multiple cardioversions were performed in 100 (12%) cardioverted patients: 2 cardioversions in 99 patients and 3 cardioversions in 1 patient. In comparing the matched cardioversion and noncardioversion cohorts, patients who underwent cardioversion were more likely have AF progression at first follow-up (15.4% vs 10.2%, P = .0003) and second follow-up (19.4% vs 14.2%, P b .0001) ( Table II) . The OR of AF progression during 1 of the 2 visits after cardioversion was 1.6 (95% CI 1.2-2.2, P = .0012) in those who underwent cardioversion compared with matched patients who were not cardioverted.
Symptoms and quality of life after cardioversion
For patients within the matched cohort, half of the cardioverted patients had no change in EHRA symptom score after cardioversion, whereas 34% and 15% had improvement and worsening in symptoms, respectively. Overall, there was no significant improvement observed in EHRA scores in those cardioverted compared with matched controls at first follow-up (Figure 1 ). The change in AFEQT was not statistically significant for cardioversion patients (mean 9.2 ± 24.1) compared with noncardioverted patients (mean 4.6 ± 17.3, P = .25). There was no significant improvement in the AFEQT scores in those cardioverted compared with matched controls at first follow-up (Appendix 3). Among the cardioverted patients in the matched cohort, 102 (23%) patients had a TEE-guided cardioversion. Even after excluding these TEE-guided cardioversion patients, the matched cardioversion patients had similar change in EHRA (50% no change, 33% improvement, and 16% worsening) and AFEQT scores (mean 6) to the overall matched cohort.
Cardiovascular outcomes after cardioversion
As shown in Table III , the rates of death, myocardial infarction, and stroke or transient ischemic accident were low and similar in both matched cohorts. Most of all-cause hospitalizations were cardiovascular hospitalizations in both the cardioverted (79% of all-cause hospitalizations) and noncardioverted (62% of all-cause hospitalizations) cohorts. The observed rate of cardiovascular hospitalization was 2-fold greater in the cardioverted patients: 43 cardiovascular hospitalizations per 100 patient-years in cardioverted patients compared with 21 per 100 patientyears in noncardioverted patients (P b .0001) (Figure 2) .
Discussion
There is a lack of data regarding the impact of cardioversion for AF on long-term patient outcomes and quality of life. In ORBIT-AF, cardioversion was performed in nearly 1 in 10 patients, and more than 10% of cardioverted patients had a repeat cardioversion. Patients who received cardioversion, including first cardioversion, were at high risk for cardiovascular rehospitalization and Abbreviations: BMI, Body mass index; COPD, chronic obstructive pulmonary disease, OSA, obstructive sleep apnea; CPAP, continuous positive airway pressure; HF, heart failure; LA, left atrial. Creatinine clearance is defined by Cockroft-Gault and reported as mL/min.
symptomatic progression of AF. Cardioversion was a marker of lower quality of life and greater symptom burden, as reflected by the baseline AFEQT and EHRA scores in cardioverted patients. There was no evidence that cardioversion was associated with alteration of the natural history of AF in terms of disease progression without concomitant rhythm control therapy. Cardioversions for AF have increased in Europe, and similar to our findings, most cardioversions were electrical.
14 Cardioversion patients in ORBIT-AF were younger than noncardioversion patients. This age discrepancy was likely due to the fact that younger patients with AF tend to have more symptoms and exertional limitation due to AF, and as supported by the findings in this study, patients with symptoms of AF get cardioverted at higher rates.
Hospitalization and cardiovascular hospitalization were more frequent in the 12 months after cardioversion compared with the matched noncardioverted patients. Nearly 3 in 5 cardioverted patients were hospitalized over the subsequent year, with more than 2 in 5 patients hospitalized for a cardiovascular cause within 1 year of cardioversion. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study similarly found that hospitalization rates were higher in patients with a rhythm control strategy (80%) relative to rate control (73%; P b .001). 5 The rates of hospitalization within 1 year of cardioversion in our study were higher than the 38% of AF patients hospitalized at 1 year based on data from MarketScan Medicare Supplemental and Coordination of Benefits Database, despite the fact that the MarketScan Medicare population was older than ORBIT-AF (77.7 vs 68.6 years). 15 The incidence of 1-year hospitalization for our noncardioverted patients was 35%, which is similar to the 31% per year rate of all-cause hospitalization that was previously reported in the overall ORBIT-AF population. 16 Even after fully adjusting for AFEQT in a subset of patients, cardioversion was not associated with lower rates of cardiovascular hospitalization. The higher rates of cardiovascular hospitalization were likely due to recurrences of AF, because almost 40% of patients had evidence of AF recurrence.
Patients in our study who did have AF recurrence after cardioversion went on to have AF progression nearly 80% of the time, demonstrating the potential need for more aggressive rhythm management strategies in patients with symptomatic AF recurrence after cardioversion. Given this, it was surprising that less than 20% of cardioverted patients not on an antiarrhythmic before cardioversion were started on one after the procedure, less than 5% of cardioverted Patients who were not in sinus rhythm or AF were in atrial flutter or paced rhythms.
Figure 1
Change in EHRA score after cardioversion for matched patients. In order of increasing severity of symptoms, the EHRA score categories are "no symptoms," "mild symptoms," "severe symptoms," or "disabling symptoms." A change score of −1 or −2 means that a patient moved 1 or 2 EHRA symptom scores toward the "disabling symptoms" side of the spectrum between precardioversion and postcardioversion. A change score of +1 or +2 means that the patient moved 1 or 2 EHRA symptom scores toward the "no symptoms" side of the spectrum between precardioversion and postcardioversion. A change score of 0 means that the patient had the same EHRA score precardioversion and postcardioversion.
patients had an ablation after cardioversion, and nearly 1 in 4 cardioverted patients had their antiarrhythmic stopped after cardioversion. A randomized trial compared serial cardioversion within 24 hours of AF onset to serial cardioversion based on routine outpatient follow-up in 144 patients with persistent AF and found that nearly 33% of patients in both cohorts had progressed to permanent AF, which was higher than the 19% AF progression seen at second follow-up in our cardioversion patients. 17 The lower frequency of AF progression in ORBIT-AF may have been related to the fact that 50% of cardioversion patients in ORBIT-AF were on an antiarrhythmic at follow-up, compared with only approximately 33% in the randomized cardioversion trial. A second trial randomized 90 persistent AF patients to a single cardioversion or serial cardioversions. All patients were treated with an antiarrhythmic for the duration of the study, and in this case, serial cardioversion in combination with antiarrhythmic therapy did increase the maintenance of sinus rhythm at 1 year. 18 This may mean that providers in clinical practice were too dependent on cardioversion and not aggressive enough with more durable rhythm control strategies.
Cardioversion was not associated with higher quality of life, despite aggressive adjustment for baseline symptoms, age, heart failure, and antiarrhythmic use. Cardioversion may have been a marker of symptomatic progression of AF, identifying patients in need of a more durable rhythm control intervention. Cardioversion likely resulted in a transient symptomatic improvement, which made cardioversion a powerful diagnostic tool in AF because it could dramatically change, potentially only for a short time, the quality of life in a patient with true, symptomatic AF. This study found that there was no association between cardioversion and longer-term quality of life measures, which may have been due to the low rates of antiarrhythmic drug use and ablation therapy after cardioversion. In patients not treated with ablation or an antiarrhythmic medication, recurrence of AF after cardioversion was as high as 70% at 4 weeks and 83% at 1 year, 9, 10 and this was consistent with our data showing that 31% of patients treated with cardioversion only (no antiarrhythmic medication or ablation) were in sinus rhythm at first and second follow-ups after cardioversion. In the absence of treatment, quality of life scores improve over time with chronic conditions because patients tend to acclimate to their limitations, and patients lose the perception of the impact of their symptoms on their quality of life. When a patient with symptomatic AF is cardioverted and later has recurrence of AF, they may be more aware of the impact of AF on their quality of life, relative to noncardioverted patients who adjust to the limitations of their symptoms over time. Identifying patients with symptomatic AF can be more challenging because of the gradual decline in functional status and corresponding patient adaptations.
Limitations
This analysis had several important limitations. Despite an aggressive propensity matching technique, as with any observational study, residual measured and unmeasured confounding may have influenced these findings. The clinical and quality of life data were not captured at consistent time intervals after cardioversion. Patients with recurrence of AF may have been made aware of their rhythm status before answering the quality of life questions. Also, the AFEQT scores were only available in a small subset of patients, so it remains unclear if trends in higher AFEQT 
Figure 2
Kaplan-Meier plot of survival free of cardiovascular hospitalization. The solid line represents the matched noncardioverted patients, whereas the dotted line represents the matched cardioverted patients.
The Kaplan-Meier plot shows the proportion of patients without cardiovascular hospitalizations over time.
scores in the cardioversion patients relative to noncardioversion patients were due to chance or were underpowered, true findings. We were unable to accurately comment on anticoagulation status at the time of cardioversion, and we were unable to correlate the timing of changes in antiarrhythmic medications to changes in rhythm status. The exact reasoning for the hospitalizations (eg, symptomatic AF, initiation of antiarrhythmic medication, or pacemaker placement) was unknown, and whether the hospitalizations were unplanned or were elective was unknown. The recurrence rates of AF after cardioversion may have been underestimated, as patients did not routinely get outpatient continuous rhythm monitoring or undergo standardized electrocardogram monitoring. Progression of AF may have been determined without ambulatory monitoring, and this was not an adjudicated end point. Although AF progression was associated with cardioversion, the cardioversion itself was unlikely the cause of the AF progression; this association may have been due to a spurious finding, a higher likelihood to label patients with permanent AF after a failed cardioversion for persistent AF, a tendency for providers to underestimate AF type before cardioversion, or the influence of residual or unmeasured confounding. In contrast to these limitations, there are several strengths of our study. First, this analysis represented the largest study ever performed of symptoms and quality of life after cardioversion. In addition, because our data were from unrestricted clinical practice, our results were more broadly applicable and generalizable. The findings consistently did not show an association between cardioversion and decreased rehospitalization, decreased AF progression, or improved quality of life within the matched population and the first-cardioversion population.
Conclusion
There was no evidence that cardioversion changes the progression of AF or quality of life in AF in the absence of more definitive rhythm control therapies. These findings may help to better inform therapeutic decision making and clinical guidelines. If patients are candidates for rhythm control, cardioversion used in combination with more aggressive rhythm control, such as antiarrhythmic therapy or ablation, may have a more favorable impact on disease progression, outcomes, and quality of life.
